secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001193125-25-112057
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio receives FDA refusal to file for ANKTIVA sBLA in NMIBC papillary indication
--------------------------------------------------------------------------------

- FDA issued Refusal to File (RTF) letter on May 2, 2025 for sBLA of ANKTIVA+BCG in BCG-unresponsive papillary NMIBC.
- Company cites unanimous January 2025 FDA leadership guidance encouraging sBLA submission; RTF called inconsistent.
- Existing approval for CIS +/- papillary (Cohort A) is unaffected; RTF pertains to papillary without CIS (Cohort B).
- Data highlighted: 96% disease-specific survival at 36 months and >82% bladder-sparing rate in the papillary cohort.
- Company requests urgent Type A meeting with FDA; former FDA Principal Deputy Commissioner Dr. Sherman supports appeal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000119312525112057/0001193125-25-112057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000119312525112057/d949868d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-112057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer